Bis(2-ethylhexyl) phthalate levels in nonuremic patients treated with extracorporeal devices.
DEHP levels after treatment were studied in 6 nonuremic psoriatic patients undergoing extracorporeal therapy. Serum DEHP levels at the end of therapy of these patients were significantly lower than that of maintenance hemodialysis patients. DEHP and/or its metabolites were excreted by the normal kidneys, although the excretion of nonmetabolized DEHP by the kidneys was minimal. There was no correlation between serum DEHP levels of these nonuremic patients and the type of artificial kidney used or the mode of therapy employed.
D001769:Blood; D004051:Diethylhexyl Phthalate / Q000097:blood* / Q000652:urine; D006801:Humans; D007688:Kidneys, Artificial / Q000009:adverse effects; D010795:Phthalic Acids / Q000097:blood*; D011143:Polyvinyl Chloride; D011565:Psoriasis / Q000097:blood / Q000628:therapy; D006435:Renal Dialysis / Q000009:adverse effects*; D013997:Time Factors; D014462:Ultrafiltration / Q000009:adverse effects* / Q000295:instrumentation
D010795:Phthalic Acids; D011143:Polyvinyl Chloride; D004051:Diethylhexyl Phthalate